HitanerceptAlternative Names: Hitenercept; Recombinant human TNF receptor p75-Fc fusion protein - Shanghai Fudan-Zhangjiang; rhTNFR(m):Fc - Shanghai Fudan-Zhangjiang; T-0001 - Shanghai Fudan-Zhangjiang
Latest Information Update: 19 Oct 2016
At a glance
- Originator Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
- Class Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins
- Mechanism of Action Tumour necrosis factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Rheumatoid arthritis